Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21

Area of Science:

• Genomics
• Oncology
• Hematology

Background:

• Diffuse large B-cell lymphoma (DLBCL) exhibits variable clinical courses despite treatment advances.
• Identifying genetic factors influencing treatment response is crucial for personalized medicine.

Purpose of the Study:

• To investigate the impact of genomic aberrations on the clinical outcomes of DLBCL patients treated with R-CHOP-21.
• To identify genetic subgroups within DLBCL with distinct prognoses.

Main Methods:

• Retrospective, multi-center study analyzing 166 DNA samples using high-density genome-wide single nucleotide polymorphism arrays (GeneChip Human Mapping 250K NspI).
• Array comparative genomic hybridization (arrayCGH) was used to detect genomic anomalies.
• Unsupervised clustering was applied to identify genetically related patient subgroups.

Main Results:

• Twenty recurrent genetic lesions significantly impacted the clinical course of DLBCL patients.
• Loss of genomic material at 8p23.1 was the most statistically significant finding, associated with 17p- and 15q- aberrations.
• Five distinct DLBCL clusters with unique genetic profiles, clinical characteristics, and outcomes were identified.

Conclusions:

• ArrayCGH can identify genetic features and patient clusters associated with differential outcomes in DLBCL treated with R-CHOP-21.
• Genomic profiling offers potential for refining prognostic stratification and guiding therapeutic strategies in DLBCL.